• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Catalyst Biosciences Inc.

    11/29/23 4:01:50 PM ET
    $CBIO
    Get the next $CBIO alert in real time by email
    RW 1 ef20015615_rw.htm RW

     
    November 29, 2023
     
    VIA EDGAR

    Division of Corporate Finance
    Securities and Exchange Commission
    100 F Street, N.E.
    Washington, D.C. 20549-7010
    Attn:  Dillon Hagius and Joe McCann


    Re:
    Gyre Therapeutics, Inc.
    Request to Withdraw Registration Statement on Form S-3
    File No. 333-275466

    Ladies and Gentlemen:
     
    Gyre Therapeutics, Inc. (the “Registrant”) previously filed the above-referenced registration statement on Form S-3 on November 13, 2023 (the “Registration Statement”).  Pursuant to Rule 477, promulgated under the Securities Act of 1933, as amended, the Registrant hereby requests that the Registration Statement, together with all exhibits and amendments thereto, be withdrawn at your earliest convenience.  The Registration Statement has not been declared effective by the Commission.
     
    The Registration Statement was filed with the Commission in connection with the resale by a selling stockholder of shares of the Registrant’s common stock, par value $0.001 per share, underlying (i) 811 shares of the Registrant’s Series X Convertible Preferred Stock, par value $0.001 per share (the “Convertible Preferred Stock”) and (ii) 811 shares of Convertible Preferred Stock issuable upon the exercise of warrants to purchase shares of Convertible Preferred Stock.
     
    The Registrant has determined not to register the securities for resale under the Registration Statement and therefore believes withdrawal of the Registration Statement to be consistent with the public interest and the protection of investors.  The Registrant represents that the selling stockholder has not effected any sales of the Registrant’s securities under the Registration Statement.
     
    Please provide a copy of the order granting withdrawal via email to our counsel, Branden C. Berns of Gibson, Dunn & Crutcher LLP at [email protected].  If you have any questions, please contact Mr. Berns at (415) 393-4631.
     
     
    Sincerely,
     
     
    /s/ Charles Wu
     
     
    Name: Charles Wu
     
    Title: Chief Executive Officer



    Get the next $CBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBIO

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Raymond James
    8/6/2021$19.00 → $18.00Outperform
    Raymond James
    More analyst ratings

    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Catalyst Biosciences downgraded by Raymond James

      Raymond James downgraded Catalyst Biosciences from Outperform to Market Perform

      11/15/21 4:49:07 AM ET
      $CBIO
    • Raymond James reiterated coverage on Catalyst Biosciences with a new price target

      Raymond James reiterated coverage of Catalyst Biosciences with a rating of Outperform and set a new price target of $18.00 from $19.00 previously

      8/6/21 12:08:01 PM ET
      $CBIO
    • Stephens resumed coverage on Catalyst Biosciences with a new price target

      Stephens resumed coverage of Catalyst Biosciences with a rating of Overweight and set a new price target of $19.00 from $18.00 previously

      4/29/21 1:31:07 PM ET
      $CBIO